Free University of Amsterdam
Free University of Amsterdam researchers describe recent findings
Published in Lab Law Weekly, June 23rd, 2006
This trend article about Free University of Amsterdam is an immediate alert from LawRx to identify developing directions of research.
Study 1: The evaluation of risks and benefits of phase II cancer clinical trials by institutional review board (IRB) members was assessed.
According to recent research from the Netherlands, "There are indications that institutional review board (IRB) members do not find it easy to assess the risks and benefits in medical experiments, although this is their principal duty. This study examined how IRB members assessed the risk/benefit...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2006-06-23)
More Articles from Lab Law Weekly
- Aegate
Pilot study confirms use of Aegate's technology to combat pharmaceutical fraud - Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals to acquire Quill Medical - Biotechnology Industry Organization
BIO names Tom DiLenge as general counsel - Chimerix, Inc.
Chimerix acquires lead compound library of antiviral agents from University of Michigan - Elsevier MDL
Electronic laboratory notebooks for chemistry and biology are reviewed - ExonHit Therapeutics
ExonHit files patent on a panel of genes for the diagnosis of Alzheimer disease from blood - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
